Outcomes after progression of disease with anti–PD‐1/PD‐L1 therapy for patients with advanced melanoma

Greater than one‐half of patients with melanoma who are treated with antibodies blocking programmed cell death protein 1 receptor (anti–PD‐1) experience disease progression. The objective of the current study was to identify prognostic factors and outcomes in patients with metastatic melanoma that progressed while they were receiving anti–PD‐1 therapy.

[1]  Douglas B. Johnson,et al.  Association of Anti-Programmed Cell Death 1 Cutaneous Toxic Effects With Outcomes in Patients With Advanced Melanoma. , 2019, JAMA oncology.

[2]  Vinay Prasad,et al.  Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs , 2019, JAMA network open.

[3]  J. Wolchok,et al.  Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. , 2019 .

[4]  D. Schadendorf,et al.  Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. , 2019, The New England journal of medicine.

[5]  J. Sosman,et al.  Clinical Correlates of Response to Anti-PD-1–based Therapy in Patients With Metastatic Melanoma , 2019, Journal of immunotherapy.

[6]  J. Wolchok,et al.  Correction: Baseline tumor size is an research independent prognostic factor for overall survival in patients with melanoma treated with pembrolizumab(Clin Cancer Res (2018)24(4960–7)DOI: 10.1158/1078-0432.CCR-17-2386) , 2018 .

[7]  J. Wolchok,et al.  Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab , 2018, Clinical Cancer Research.

[8]  Douglas B. Johnson,et al.  Emerging biomarkers for cancer immunotherapy in melanoma. , 2017, Seminars in cancer biology.

[9]  A. Ribas,et al.  Mechanisms of Resistance to PD-1 and PD-L1 Blockade , 2018, Cancer journal.

[10]  E. Jaffee,et al.  Tumor Mutational Burden and Response Rate to PD-1 Inhibition. , 2017, The New England journal of medicine.

[11]  Jeffrey E Gershenwald,et al.  Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual , 2017, CA: a cancer journal for clinicians.

[12]  J. Sosman,et al.  Clinical Features of Acquired Resistance to Anti–PD-1 Therapy in Advanced Melanoma , 2017, Cancer Immunology Research.

[13]  R. Sullivan,et al.  Sequencing Treatment in BRAFV600 Mutant Melanoma: Anti-PD-1 Before and After BRAF Inhibition , 2017, Journal of immunotherapy.

[14]  M. Amagai,et al.  Nivolumab for advanced melanoma: pretreatment prognostic factors and early outcome markers during therapy , 2016, Oncotarget.

[15]  Yu Shyr,et al.  Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade , 2016, Cancer Immunology Research.

[16]  Matthew Wongchenko,et al.  Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. , 2016, The Lancet. Oncology.

[17]  A. Iafrate,et al.  Impact of NRAS Mutations for Patients with Advanced Melanoma Treated with Immune Therapies , 2015, Cancer Immunology Research.

[18]  J. Utikal,et al.  Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. , 2014, The New England journal of medicine.

[19]  C. Tzen,et al.  Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma , 2011, Pigment cell & melanoma research.

[20]  J. Gershenwald,et al.  Staging and prognosis of cutaneous melanoma. , 2011, Surgical oncology clinics of North America.

[21]  Li-E. Wang,et al.  Clinical Correlates of NRAS and BRAF Mutations in Primary Human Melanoma , 2010, Clinical Cancer Research.

[22]  P. Leder,et al.  Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. , 2006, Cancer cell.